STERIS plc (NYSE:STE) announced a quarterly dividend on Monday, November 2nd, Zacks reports. Shareholders of record on Tuesday, November 24th will be given a dividend of 0.40 per share by the medical equipment provider on Friday, December 18th. This represents a $1.60 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date is Monday, November 23rd.
STERIS has raised its dividend payment by 34.0% over the last three years and has increased its dividend annually for the last 14 consecutive years. STERIS has a dividend payout ratio of 28.4% meaning its dividend is sufficiently covered by earnings. Equities analysts expect STERIS to earn $6.43 per share next year, which means the company should continue to be able to cover its $1.60 annual dividend with an expected future payout ratio of 24.9%.
STERIS stock opened at $196.05 on Friday. STERIS has a one year low of $105.69 and a one year high of $196.80. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.71 and a current ratio of 2.29. The business has a fifty day moving average of $184.96 and a two-hundred day moving average of $164.53. The company has a market cap of $16.73 billion, a P/E ratio of 40.76 and a beta of 0.66.
STE has been the subject of a number of recent analyst reports. JMP Securities raised their target price on STERIS from $180.00 to $200.00 in a report on Thursday, October 8th. Robert W. Baird lifted their price target on STERIS from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. Stephens raised their target price on shares of STERIS from $170.00 to $200.00 in a report on Wednesday, October 7th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a report on Friday. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $189.50.
In other news, VP John Adam Zangerle sold 2,000 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $167.00, for a total value of $334,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard C. Breeden sold 25,000 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $152.67, for a total transaction of $3,816,750.00. Following the completion of the sale, the director now directly owns 31,681 shares of the company’s stock, valued at approximately $4,836,738.27. The disclosure for this sale can be found here. Insiders have sold 58,602 shares of company stock valued at $9,783,141 in the last ninety days. 1.20% of the stock is currently owned by company insiders.
STERIS Company Profile
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Further Reading: CD Ladder
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.